Peripheral blood stem cell transplant (PBSCT) in a large series of patients with poems syndrome  by Dispenzieri, A. et al.
should be compared with G-CSF mobilized peripheral blood stem
cell collection.
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NEUTROPENIA AND THROMBOCYTOPENIA INDUCED BY G-CSF ADMIN-
ISTRATION IN HEALTHY PBSC ALLOGENEIC DONORS: HOW LONG
SHOULD BE PROLONGED HEMATOLOGICAL AND CLINICAL SURVEIL-
LANCE?
Tassi, C., Anna, N., Valeria, G., Roberto, C. Medical Transfusion
Service-Sant’orsola, Bologna, Bologna, Italy
From February 1998, one hundred and twenty peripheral blood
stem cell (PBSC) healthy donors were treated with G-CSF for 4-7
days and submitted to leukoapheresis courses in the Apheresis Unit
of our Service. All were enrolled on short and long-term clinical
and hematological surveillance protocol for a ﬁve year time. To-
date, 95 donors are evaluable: overall mean follow-up time is 31
months, being 36 months in 45 and 12 months in 13 subjects.
Main clinical adverse effects to Lenograstim were headhache
(65%), musculo-skeletal pain (78%) and fatigue (69%); no therapy
or low paracetamol doses were employed in 95% of the donors.
Pre-leukoapheresis mean platelet reduction was assessed at 23.6%
 9% and detected in 42/95 cases; an additional decrease of
absolute WBC counts, in particular due to both PMN and Lym-
phocyte low numbers, was diagnosed in 27 subjects of this group.
Pre-G-CSF administration platelet values were observed at 12
months of follow-up. Multivariate and univariate analysis demon-
strated a correlation between duration of G-CSF administration
(p.004), pre G-CSF platelet level (p.003) and decreased platelet
count before leukoapheresis. At this regard, PMN and or lympho-
cyte lower values were counted in 75 out of 95 donors two weeks
after G-CSF administration, whereas PMN and Lymphocytes
were signiﬁcantly decreased in 43 out of the 75 subjects (-39.3%
and -30%, respectively). Transient PMN count below 1000/ul was
detected in 4/43 cases. Finally, in 12/43 donors pre mobilization
number of PMNs or Lymphocytes were reached only after 24
months of follow-up time. Univariate and multivariate analysis
demonstrated strict correlation between-n reduction at 4, 8,
and 12 months of follow-up, and G-CSF administration days
(p.0021)  pre-mobilization PMN absolute counts (p.003). Sex
and age of patients did not signiﬁcantly correlate with WBC
decremental trend; however, isolated PMN low values were more
frequently observed in young patients, since in this group mean age
was 38.5  15 yrs in comparison to lymphocytopenic donors
(44.7 5 yrs). Taken altogether, these results seem to demonstrate
in younger PBSC donors treated with G-CSF for more than ﬁve
days, negative effects on myelopoiesis lasting two years, without
any ﬁndings of haematological disorders or clinical sign of disease.
In these limited cases, a hematocromocytometric observation may
be prudentially prolonged over ﬁve years.
AUTOLOGOUS
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PEGFILGRASTIM (NEULASTA) FOLLOWING CHEMOTHERAPY LEADS
TO SUCCESSFUL MOBILIZATION OF HEMATOPOIETIC PROGENITOR
CELLS AMONG TRANSPLANT PATIENTS WITH VARIOUS DIAGNOSES
Mandanas, R.A.1, Underwood, B.J.1, Geister, B.V.1, Smith, J.W.2 1.
Western Oklahoma Blood and Marrow Transplant Program, Cancer
Care Associates, Oklahoma City, OK;2. Oklahoma Blood Institute, Okla-
homa City, OK
Filgrastim has been traditionally used following chemotherapy to
mobilize hematopoietic progenitor cells. Doses of 5-10 g/kg/day
subcutaneously have been given until recovery of WBC counts to
over 5.0  103/L before initiating leukapheresis. Pegﬁlgrastim
(Neulasta™) produced by covalently binding a 20-kd monome-
thoxypolyethylene glycol molecule to the N-terminal methionyl
residue of ﬁlgrastim has a much longer half-life allowing for a
single 6 mg subcutaneous injection with similar efﬁcacy and safety
proﬁle as ﬁlgrastim in reducing the duration of severe chemother-
apy-induced neutropenia. Thirteen patients with various diagnoses
(6 Myeloma, 4 NHL, 1 breast cancer, 1 seminoma, 1 CLL) re-
ceived pegﬁlgrastim 6 mg single injection 1 day after completing
mobilization chemotherapy (cytoxanetoposide  8; cytoxan  2;
ICE  Rituximab  2; taxotereadriamycincytoxan  1). The
median age was 56 years (28-71) with 8 females and 5 males.
Leukapheresis processing 3 times the estimated blood volume was
initiated beginning recovery of total WBC count to at least 5.0 
103/L. The minimum target of 2.5  106/kg CD34 cell count
was achieved 100% in all 13 patients after only one day of leuka-
pheresis. The optimal target of 5.0  106/kg CD 34 cell count
was obtained in 85% (11/13 patients) in a single day of collection.
The mean CD34 cell count collected in the ﬁrst day was 16.8 
106/kg (median 13.6, range 2.5 – 45.5). Two patients (1 CLL, 1
Myeloma with CLL) had their harvested product CD34-selected
before cryopreservation. All patients engrafted following their au-
totransplants. Engraftment data were as predicted for peripheral
blood stem cell recovery times (Time to ANC of 500/L: mean
10.3 days, range 8-11 and time to Platelet count 20  103/L:
mean 11.5 days, range 9-15). In conclusion, pegﬁlgrastim given as
a single 6 mg subcutaneous injection after chemotherapy is a viable
alternative to multiple daily injections of ﬁlgrastim for the mobi-
lization of hematopoiteic progenitor cells.
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PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) IN A LARGE
SERIES OF PATIENTS WITH POEMS SYNDROME
Dispenzieri, A.1, Moreno-Aspitia, A.2, Lacy, M.Q.1, Colon-Otero, G.2,
Tefferi, A.1, Litzow, M.R.1, Gertz, M.A.2 1. Mayo Clinic, Rochester,
MN; 2. Mayo Clinic, Jacksonville, FL
Background: The POEMS syndrome is characterized by pe-
ripheral neuropathy (PN), clonal plasma cell disorder (PCD), or-
ganomegaly, endocrinopathy, skin changes, edema, sclerotic bone
lesions, and thrombocytosis. Based on the improved response rates
observed with PBSCT in patients with other PCD, autologous
Table. Summary of Serious Marrow Complications
3
Symptom
Nature/
Duration
2Proximal
Cause
Acute/
Atypical
Acute/
Known Cancer
Herniated
Disk
Prolonged
Recovery/
Mild
Prolonged
Recovery/
Moderate-
Severe Total
Anesthesia 15
(75%)
28
(97%)
0 0 2
(7%)
0 45
(36%)
Infection 1 (5%) 0 0 0 0 0 1
(1%)
Mechanical
Injury
4 (20%) 0 0 0 25
(93%)
40
(100%)
69
(55%)
Unrelated/
Other
0 1
(3%)
6
(100%)
3
(100%)
0 0 10
(8%)
Total 20 29 6 3 27 40 125
Table. Variation of PMN in 24 Months of Follow-up Time
T0 PMN
counts
%
Decre-
ment
 14
%
Decre-
ment
 4m
%
Decre-
ment
 8m
%
Decre-
ment
 12m
%
Decre-
ment
 24m
10 Patients
lymphopenic 3310  320
not
change
not
change
not
change
not
change
not
change
22 Patients
neutropenic 4450  1220 37.5  13.9 12  5 8  3 9  3.5 12.4  4
43 Patients ly
 neutro-
penic  3855  456 39.5  14 15  3.7 10  2.8 13  6 21.6  9
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PBSCT may be an attractive treatment option for patients with
POEMS syndrome. Methods: Between March 1999 and February
2003, 11 patients with POEMS syndrome underwent PBSCT at
Mayo Clinic Rochester and Jacksonville. Conditioning regimens
were single agent melphalan (n  9) and BEAM (n  1). All
received a minimum of 4.4  106 CD34 autologous PBSC/kg.
Standard supportive care with prophylactic antibiotics and growth
factor support was provided. Results: All but one had a severe
rapidly progressive sensorimotor PN involving both upper and
lower extremities, 7 wheelchair conﬁned. One patient had sensory
neuropathy without signiﬁcant motor involvement. All but one was
male. A monoclonal lambda PCD was documented in all patients,
and two had biopsy proven Castleman Disease. Median age was 50
years (range 19-62). Seven had organomegaly (5 splenomegaly; 2
hepatomegaly; and 3 lymphadenopathy). Both endocrinopathy and
skin changes were present in 9 patients. Seven had thrombocytosis
and/or erythrocytosis, and 8 had sclerotic bone lesions (diffuse in 5,
solitary lesion in 3). Using the Bardwick Criteria, the median
number of POEMS features was 5 (range 2-5). The median num-
ber of therapeutic regimens prior to PBSCT was 3 (range 0-6).
From ﬁrst symptoms and from diagnosis of POEMS the median
times to transplant were 27 and 10 months (ranges 4-180 and
2-180), respectively. All but one patient had signiﬁcantly abnormal
pre-transplant pulmonary function tests. Of the 8 evaluable pa-
tients, all have had a hematologic response and 7 have had neuro-
logic improvement at a median follow-up of 6 months. Other
symptoms including fatigue, organomegaly, pulmonary compro-
mise, hyperpigmentation and extravascular volume overload have
improved substantially in affected patients. Since February 2003,
an additional 4 patients have been transplanted, but are not yet
evaluable. Conclusions: PBSCT for POEMS syndrome may re-
sult in a high hematologic response rate and improvement in
peripheral neuropathy and systemic symptoms. The outcome of
these patients will be updated at the meeting.
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GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE AFTER AUTOLO-
GOUS STEM CELL TRANSPLANT: INCIDENCE, OUTCOME, AND RISK
FACTORS
Holmberg, L.A.1,2, Gooley, T.1,2, Kikuchi, K.1, Adams, K.M.1,2, Schoch,
G.H.1,2, Bensinger, W.I.1,2, McDonald, G.B.1,2 1. Fred Hutchinson
Cancer Research Center, Seattle, WA; 2. University of Washington,
Seattle, WA
GVHD has been described in the skin, intestinal mucosa, and
liver after autologous stem cell transplantation. The mechanisms
and risk factors for non-cyclosporine-induced autologous GVHD
are unknown. Methods: We reviewed 681 consecutive autologous
transplant patients treated between 1995–1999 to determine the
incidence of response to treatment, and risk factors for developing
gastrointestinal GVHD. GVHD was deﬁned by persistent symp-
toms, mucosal abnormalities at endoscopy, histology showing ap-
optotic crypt-cells and lymphoid inﬁltrates, and absence of infec-
tion. Results: The incidence of GVHD was 90/681 (13%), with
nausea, vomiting, and anorexia in 90% and diarrhea in 37%. The
mean time to onset was day  15 and endoscopic diagnosis day 
45. Treatment with prednisone (1 mg/kg/d) for 10-14 days fol-
lowed by a taper effected durable responses in 72%; an additional
19% responded to a second course. GVHD developed in 18% of
the women and 8% of the men. Signiﬁcant risk factors in univariate
analysis included female sex (p  .0009), diagnosis of breast cancer
(BRCA) (p  .0001), IL-2 therapy (p  .04), Busulfan/Melphalan/
Thiotepa (BUMELTT) conditioning (p  .03) and use of PBSC
(p  .025). All cases of GVHD were in patients who received
PBSCs. Females with BRCA were 3.3x more likely to develop
GVHD than males with any diagnosis (95% C.I., 1.9-5.8, p 
.0001). Gravidity and parity of females did not statistically affect
the risk for developing GVHD. Since women were more likely to
receive BUMELTT conditioning, the data was analyzed adjusting
for this regimen. A multivariate logistic regression model revealed
the following: (see Table 1)
The hazard of mortality (or relapse) of patients with GVHD
compared to those without was not signiﬁcantly different for the
cohort as a whole nor across different genders/diagnoses (HR:
0.89, 95% C.I. 0.64-1.22, p  .46). Conclusions: Gastrointestinal
GVHD developed in 13% of 681 autologous transplant recipients
and was responsive to short courses of prednisone. Female sex
appears to be the most important risk factor. Although
BUMELTT appears to increase the odds of developing GVHD,
female gender and underlying disease carried an increased risk for
developing GVHD independent of the conditioning regimen.
GRAFT PROCESSING
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SIGNIFICANCE OF LOW PERIPHERAL BLOOD CD34 CELL NUMBERS
PRIOR TO LEUKAPHERESIS: SHOULD THE 5/L THRESHOLD RE-
QUIRED FOR APHERESIS BE CHANGED?
Gidron, A., Doyle, M., Gordon, L., Singhal, S., Tallman, M., Williams,
S., Winter, J., Tomblyn, M., Verma, A., Mehta, J. Northwestern
University, Chicago
The pre-apheresis peripheral blood CD34 cell count
(PBCD34) is a strong predictor of the CD34 cell collection. The
ﬁnal yield is also affected by the blood volume processed and the
CD34 cell collection efﬁciency (CE). It is common practice to
apherese only when PBCD34 is 5/L to avoid poor yields. How-
ever, many patients mobilize stem cells poorly, and the only way to
get enough cells is to collect small numbers at a time over several
days. Omitting apheresis because PBCD34 is below a set value may
prevent them from undergoing a transplant. There are other pit-
falls with this practice: it does not take the patient’s weight into
account, and it ignores the possibility of improving the collection
by processing more blood. Of 485 autologous harvests on Cobe
Spectra over 30 months where PBCD34 was available, 104 were
done with PBCD34 5/L. Volume processed was 15 L (n  57)
or 20 L (n  47). A collection of 0.3  106 CD34 cells/kg was
considered acceptable as this daily yield over a week could add up
to 2  106/kg-enough for an autograft. 60 harvests (58%) had
yields of 0.3; with 49% being 0.4, 38% being 0.5 and 23%
being 0.6. CE for these 104 harvests was 9-145% (median 55%)
compared to 7-132% (median 45%) for the other 381 harvests
performed with PBCD34 5/L (P  0.0001). CE for the 60
harvests with CD34 yields 0.3 was 30-145% (median 70) com-
pared with 9-118% (median 35%) for the 44 with CD34 yields
0.3 (P  0.0001). This suggests that part of the reason for poor
collection was low CE in addition to poor mobilization. The
problem of low CE may be solved in part by using more experi-
enced operators if the mononuclear cell protocol is used for
apheresis or using an automated collection protocol such as
AutoPBSC. These data show that an arbitrary PBCD34 threshold
of 5/L is inappropriate to deny apheresis. We suggest using the
following formula for patients with PBCD34 5/L to decide
about appropriateness of apheresis: 14n/w; where n 
PBCD34/L and w  ideal body weight in kg. A 20 L apheresis
with 70% CE is assumed (20  0.7  14). If 14n/w is 0.3,
apheresis should be performed. This approach is more logical than
using an absolute threshold, and ensures that patients are not
deprived of the opportunity of stem cell collection and autotrans-
plantation. We conclude that it is clinically inappropriate to set an
arbitrary minimum PBCD34 threshold for apheresis. This practice
Table.
Gender/diagnosis O.R. 95% C.I. P Value
Male/lymphoma, myeloma, or hem.
malignancy 1 — —
Female/BRCA 3.4 1.8-6.6 .0002
Female/lymphoma, myeloma, or hem.
malignancy 2.9 1.4-6.0 .003
Male/other diagnoses 3.0 1.2-7.5 .02
Female/other diagnoses 2.2 0.9-5.5 .08
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